Celcuity Announces $400M Convertible Senior Notes Offering Due 2032
Summary
Celcuity announced an offering of $400 million in convertible senior notes due 2032. This significant capital raise, representing approximately 9% of the company's market cap, follows a 25% stock decline yesterday and increased Q1 losses driven by commercialization efforts. While the financing provides capital for ongoing operations and the potential commercialization of gedatolisib, which has FDA Priority Review, the convertible nature of the notes introduces potential future dilution for existing shareholders. The PDUFA goal date for gedatolisib is July 17, 2026.
At the time of this announcement, CELC was trading at $91.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $10.60 to $151.02. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.